Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Duodenal Neoplasms 1Colorectal Neoplasms 1Barrett Esophagus 1Attenuated familial adenomatous polyposis 1Adenomatous Polyposis Coli 1Adenocarcinoma Of Esophagus 1

Interventions

Oxaliplatin 8Fluorouracil 8Nivolumab 7Leucovorin 7Paclitaxel 6Capecitabine 5Taxes 4Specimen Handling 4pembrolizumab 3Trastuzumab 3Ramucirumab 3Magnetic Resonance Spectroscopy 3Cisplatin 3zimberelimab 2zanidatamab 2Radiotherapy 2Folfox protocol 2Carboplatin 2zolbetuximab 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1tislelizumab 1quemliclustat 1obeticholic acid 1futibatinib 1dehydroftorafur 1cixutumumab 1balstilimab 1Saline Solution 1Radiofrequency Ablation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × obeticholic acid × 30 days × Clear all
NCT04939051 2026-05-13

Obeticholic Acid for Prevention in Barrett's Esophagus

National Cancer Institute (NCI)

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡